98%
921
2 minutes
20
Background: We aimed to evaluate the association of anticholinergic burden and chronic polypharmacy with the incidence of functional decline and all-cause mortality, and to determine the difference between anticholinergic burden and chronic polypharmacy among Korean older people.
Methods: This nationwide cohort study included 42,132 older people aged ≥ 65 years who underwent Korean National Health Insurance Service health examinations from 2007 to 2008. Odds ratios (ORs) and 95% confidence intervals (CIs) for abnormal Timed Up and Go (TUG) test results were assessed using multivariate logistic regression analyses. Hazard ratios (HRs) and 95% CIs for all-cause mortality until the end of 2015 were estimated using multivariable Cox proportional hazards regression analysis.
Results: Of the participants, 37.19% had abnormal TUG test results, and 7.66% of those died during the 5.7-year mean follow-up. The abnormal TUG test results OR increased by 27% among individuals with Korean Anticholinergic Burden Scale (KABS) scores ≥ 3 (OR 1.27, 95% CI 1.02-1.58) compared to those with KABS scores of 0. The HRs for all-cause mortality increased for individuals with higher KABS scores (P for trend < 0.001) or chronic polypharmacy (P for trend < 0.001) compared to those for individuals without these conditions. The combination of a higher KABS or chronic polypharmacy and abnormal TUG test results increased the risk of all-cause mortality (All P for trend < 0.001).
Conclusion: Anticholinergic drug burden shows a better association with functional decline than chronic polypharmacy, and the use of medications and functional decline may be important risk factors for all-cause mortality among older people.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10807110 | PMC |
http://dx.doi.org/10.1186/s12877-024-04692-0 | DOI Listing |
Neurol Ther
September 2025
Dayton Psychiatric Associations, Dayton, OH, USA.
Introduction: Tardive dyskinesia (TD), a persistent and often debilitating movement disorder, is associated with prolonged exposure to dopamine receptor-blocking agents. Individuals aged ≥ 60 years are at increased risk for TD and TD-related burden (e.g.
View Article and Find Full Text PDFDement Neuropsychol
August 2025
Hospital Santa Marcelina, São Paulo SP, Brazil.
Unlabelled: Anticholinergic burden (ACB) and polypharmacy are poorly studied in the context of primary care in Brazil.
Objective: To evaluate the ACB and polypharmacy of individuals with suspected dementia referred from primary care to tertiary dementia outpatient clinics in Brazil.
Methods: We performed a cross-sectional study in two tertiary dementia clinics.
J Spinal Cord Med
September 2025
Department of Physical Medicine and Rehabilitation, Ankara City Hospital, Ankara, Turkey.
Context: Individuals with suprasacral spinal cord injury (SCI) often face significant clinical and quality-of-life (QoL) burdens due to neurogenic detrusor overactivity (NDO). Transcutaneous tibial nerve stimulation (TTNS) is a non-invasive neuromodulation technique that may serve as a treatment option, but evidence regarding its effectiveness in anticholinergic-refractory NDO remains limited.
Objectives: To evaluate the effectiveness of TTNS on urodynamic parameters in individuals with SCI who have anticholinergic-refractory NDO.
Basic Clin Pharmacol Toxicol
October 2025
Faculty of Medicine, University of Southampton, Southampton, UK.
Background: Anticholinergic medication use is increasing, particularly among older adults due to polypharmacy and comorbidities. High anticholinergic burden is linked to adverse outcomes such as reduced mobility and increased dementia risk. Acute hospital stays may offer an opportunity to address this often-overlooked issue.
View Article and Find Full Text PDFBr J Clin Pharmacol
August 2025
Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Medication review in the hospital is an effective tool for identifying inappropriate prescribing, but not every patient can receive one due to resource constraints. Thus, it is important to identify patients who stand to benefit most from medication review. Patients are typically identified for medication review based on number of medications and age, but this may not be the most efficient strategy for identifying patients at high risk of future adverse clinical outcomes.
View Article and Find Full Text PDF